NRXP · NRX Pharmaceuticals, Inc.
$4.18
-0.09 (-2.11%)
At close · Jul 20
Market Cap
$151.44M
Shares
36.23M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jonathan Javitt | Chairman | $630,198 |
| Richard Narido | CFO | $298,015 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jonathan Javitt | Chairman | $873,696 |
| Stephen Willard | CEO | $799,871 |
| Richard Narido | CFO | — |